• The CAMBISeq test (Cancer Analysis Mutational Burden Instability Sequencing) is a cutting-edge diagnostic tool that uses Next Generation Sequencing (NGS) to analyze the genetic profile of cancer. This advanced test provides insights into mutations and genetic variations that can guide personalized treatment decisions, particularly for immunotherapy or targeted therapies. Here’s how it works and its key benefits:

How CAMBISeq Works

1. Sample Collection
   • A blood sample or tumor biopsy is used to extract DNA and RNA for analysis.
2. Next Generation Sequencing (NGS)
   • DNA and RNA analysis: The test examines the genetic material to detect splice variants, gene fusions, and other critical genetic alterations.
   • High coverage sequencing: This ensures the detection of even rare mutations, providing a comprehensive mutational profile.
3. Analysis of Mutational Burden
   • The test quantifies the tumor mutational burden (TMB), a key factor in predicting the effectiveness of immune checkpoint inhibitors (ICIs).
   • A higher number of mutations typically correlates with a better response to ICIs, enhancing treatment outcomes.
4. Identification of Beneficial Mutations
   • The test identifies mutations that align with:
     • FDA-approved treatments for specific cancers.
     • Therapies currently available in clinical trials.

Key Applications of CAMBISeq

1. After First-Line Therapies
   • Typically used when standard therapies are no longer effective, CAMBISeq explores alternative treatment options, including immunotherapy, targeted therapies, or clinical trials.
2. Personalized Cancer Treatment
   • Provides actionable insights for tailoring treatment to the patient’s unique genetic profile.
3. Efficacy Prediction
   • Assesses the likelihood of success with immunotherapy or targeted therapies, improving precision in treatment planning.

Key Benefits of CAMBISeq

1. Guides Advanced Treatment Options:
   • Identifies genetic mutations linked to therapies, including FDA-approved and experimental options in clinical trials.
2. Predicts Immunotherapy Effectiveness:
   • Evaluates tumor mutational burden to determine if immune checkpoint inhibitors are likely to be effective.
3. Detects Rare Mutations:
   • High coverage sequencing ensures even rare genetic alterations are identified, providing a complete picture of the cancer's genetic profile.
4. Dual DNA and RNA Analysis:
   • Offers a detailed view of genetic activity, including splice variants and fusions, which may inform treatment.
5. Expands Treatment Opportunities:
   • For patients who have exhausted first-line therapies, CAMBISeq reveals additional paths for care, including clinical trials and experimental treatments.

Who Should Consider CAMBISeq?

• Patients with advanced cancer who have not responded to standard therapies.
• Those exploring immunotherapy or targeted treatments as alternatives.
• Individuals seeking eligibility for clinical trials based on genetic mutations.

The CAMBISeq test is a powerful tool in precision oncology, equipping patients and healthcare providers with the insights needed to explore cutting-edge treatments. By uncovering critical genetic information, it paves the way for personalized, innovative cancer care that maximizes the potential for successful outcomes.